Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis

NCT04996875 is registered in ClinicalTrials.gov with Cogent Biosciences, Inc. as lead sponsor.

NCT NCT04996875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04996875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis
Lead sponsor
Cogent Biosciences, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
November 9, 2021
Completion date
July 31, 2027
Enrollment
140 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

advanced systemic mastocytosis (advsm), aggressive systemic mastocytosis (asm), mast cell leukemia (mcl), sm with an associated hematologic neoplasm (sm-ahn)